Impact of Polypharmacy on Candidate Biomarker miRNomes for the Diagnosis of Fibromyalgia and Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Striking Back on Treatments

doi 10.20944/preprints201902.0134.v1
Full Text
Abstract

Available in full text

Date
Authors
Publisher

MDPI AG

Related search

Interventions for the Treatment and Management of Chronic Fatigue Syndrome/Myalgic Encephalomyelitis

Quality and Safety in Health Care
2002English

Pathological Mechanisms Underlying Myalgic Encephalomyelitis/Chronic Fatigue Syndrome

2019English

Cell-Based Blood Biomarkers for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome

2020English

The Neuroinflammatory Etiopathology of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)

Frontiers in Physiology
Physiology
2017English

Differing Case Definitions Point to the Need for an Accurate Diagnosis of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome

Fatigue: Biomedicine, Health and Behavior
MedicineEnvironmentalPublic HealthBehavioral NeuroscienceOccupational Health
2017English

A New Look at Chronic Fatigue Syndrome/Myalgic Encephalomyelitis

Journal of Clinical Pathology
MedicineForensic MedicinePathology
2006English

Reviewing the Impact of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome on Daily Functioning Using a Holistic Model It’s Implication on Intervention

Alternative, Complementary & Integrative Medicine
2015English

A Case Definition for Children With Myalgic Encephalomyelitis/Chronic Fatigue Syndrome

Clinical medicine. Pediatrics
2008English

Genome-Epigenome Interactions Associated With Myalgic Encephalomyelitis/Chronic Fatigue Syndrome

Epigenetics
Cancer ResearchMedicineMolecular Biology
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy